SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE

被引：44

作者：

Gane, E. J. ^{[1
]}

Hyland, R. H. ^{[2
]}

An, D. ^{[2
]}

Pang, P. S. ^{[2
]}

Symonds, W. T. ^{[2
]}

Mchutchison, J. G. ^{[2
]}

Stedman, C. A. ^{[3
]}

机构：

[1] Auckland Clin Studies, Auckland, New Zealand

[2] Gilead Sci Inc, Foster City, CA USA

[3] Christchurch Clin Studies Trust, Christchurch, New Zealand

来源：

关键词：

D O I：

10.1016/S0168-8278(14)60008-8

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：S3 / S4

页数：2